Compare Abbott Laboratories (ABT) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs FuelCell Energy Inc — how do they compare? Abbott Laboratories trades at $95.33 (market cap $166.94B), while FuelCell Energy Inc trades at $22.94 (market cap $1.76B). The key difference: Abbott Laboratories is far larger — about 94.9× FuelCell Energy Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals.
| ABT | FCEL | |
|---|---|---|
Market Cap | $166.94B | $1.76B |
Sector | Health | Industrials |
52-Week High | $136.62 | $36.01 |
52-Week Low | $82.57 | $3.92 |
Enterprise Value | $193.69B | $1.60B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
FCEL trades at $25.96, down 7.65% amid a $200 million stock offering announcement, yet maintains a bullish technical signal with support near $25. Revenue grew to $158.16M in 2025, but profitability remains challenged with a net income margin of -132.41%. Recent news highlights a 5 GW proposal pipeline, with 90% tied to data center power demand, and a $49 million EXIM financing boost for global expansion.
The outlook is speculative; growth potential from AI-driven data center deals and clean energy exports is offset by persistent losses, negative cash flow from operations, and dilution risk from equity offerings. Analyst consensus is mixed with a $20.13 price target, suggesting caution despite bullish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
